Vitamin D: Pharmacokinetics and safety when used in conjunction with the pharmaceutical drugs used in cancer patients: A systematic review

9Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

Abstract

Vitamin D has reported anti-cancer and anti-inflammatory properties modulated through gene transcription and non-genomic signaling cascades. The purpose of this review was to summarize the available research on interactions and pharmacokinetics between vitamin D and the pharmaceutical drugs used in patients with cancer. Hypercalcemia was the most frequently reported side effect that occurred in high dose calcitriol. The half-life of 25(OH)D3 and/or 1,25(OH)2D3 was found to be impacted by cimetidine; rosuvastatin; prednisone and possibly some chemotherapy drugs. No unusual adverse effects in cancer patients; beyond what is expected from high dose 1,25(OH)2D3 supplementation, were revealed through this review. While sufficient evidence is lacking, supplementation with 1,25(OH)2D3 during chemotherapy appears to have a low risk of interaction. Further interactions with vitamin D3 have not been studied.

Cite

CITATION STYLE

APA

Kennedy, D. A., Cooley, K., Skidmore, B., Fritz, H., Campbell, T., & Seely, D. (2013, March). Vitamin D: Pharmacokinetics and safety when used in conjunction with the pharmaceutical drugs used in cancer patients: A systematic review. Cancers. https://doi.org/10.3390/cancers5010255

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free